These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 7916162)
1. Rating of medication influences (ROMI) scale in schizophrenia. Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162 [TBL] [Abstract][Full Text] [Related]
2. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Löffler W; Kilian R; Toumi M; Angermeyer MC Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568 [TBL] [Abstract][Full Text] [Related]
3. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia. Sapra M; Vahia IV; Reyes PN; Ramirez P; Cohen CI Schizophr Res; 2008 Dec; 106(2-3):348-55. PubMed ID: 18851906 [TBL] [Abstract][Full Text] [Related]
4. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Yamada K; Watanabe K; Nemoto N; Fujita H; Chikaraishi C; Yamauchi K; Yagi G; Asai M; Kanba S Psychiatry Res; 2006 Jan; 141(1):61-9. PubMed ID: 16318875 [TBL] [Abstract][Full Text] [Related]
5. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Santone G; Rucci P; Muratori ML; Monaci A; Ciarafoni C; Borsetti G Psychiatry Res; 2008 Apr; 158(3):324-34. PubMed ID: 18262656 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rosa MA; Marcolin MA; Elkis H Braz J Psychiatry; 2005 Sep; 27(3):178-84. PubMed ID: 16224604 [TBL] [Abstract][Full Text] [Related]
7. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited. Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198 [TBL] [Abstract][Full Text] [Related]
8. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241 [TBL] [Abstract][Full Text] [Related]
9. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Kampman O; Lehtinen K; Lassila V; Leinonen E; Poutanen O; Koivisto A Schizophr Res; 2000 Oct; 45(3):223-34. PubMed ID: 11042440 [TBL] [Abstract][Full Text] [Related]
10. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients. Sapra M; Weiden PJ; Schooler NR; Sunakawa-McMillan A; Uzenoff S; Burkholder P Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):199-206. PubMed ID: 23428784 [TBL] [Abstract][Full Text] [Related]
11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy]. Krausz M; Sorgenfrei T Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155 [TBL] [Abstract][Full Text] [Related]
14. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893 [TBL] [Abstract][Full Text] [Related]
15. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. Mueser KT; Sayers SL; Schooler NR; Mance RM; Haas GL Am J Psychiatry; 1994 Oct; 151(10):1453-62. PubMed ID: 7916540 [TBL] [Abstract][Full Text] [Related]
16. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. de Haan L; Weisfelt M; Dingemans PM; Linszen DH; Wouters L Psychopharmacology (Berl); 2002 Jun; 162(1):24-8. PubMed ID: 12107613 [TBL] [Abstract][Full Text] [Related]
17. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Garavan J; Browne S; Gervin M; Lane A; Larkin C; O'Callaghan E Compr Psychiatry; 1998; 39(4):215-9. PubMed ID: 9675506 [TBL] [Abstract][Full Text] [Related]
18. [Subjective perception of the effect of neuroleptics by outpatient schizophrenic patients: a cross-sectional study]. Bonsack C; Conus P; Philippoz R; Bovet J; Spagnoli J; Dufour H Encephale; 1998; 24(4):315-23. PubMed ID: 9809236 [TBL] [Abstract][Full Text] [Related]
19. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. Linden M; Scheel T; Eich FX J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647 [TBL] [Abstract][Full Text] [Related]
20. Quality of life in schizophrenia: insight and subjective response to neuroleptics. Browne S; Garavan J; Gervin M; Roe M; Larkin C; O'Callaghan E J Nerv Ment Dis; 1998 Feb; 186(2):74-8. PubMed ID: 9484306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]